Department of General Medicine, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Ren Fail. 2023;45(2):2278300. doi: 10.1080/0886022X.2023.2278300. Epub 2023 Nov 23.
Acute kidney injury (AKI) is a common global condition with high morbidity and mortality rates. Biomarkers can aid in the diagnosis, prediction, intervention, and outcome assessment of AKI. This study aimed to summarize the current research status and identify research hotspots for AKI biomarkers using bibliometric analysis.
Relevant original English language articles were retrieved from the Science Citation Index Expanded of the Web of Science Core Collection database, from inception to 31 December 2022. Full records and related cited references from all the documents were collected and analyzed.
A total of 16368 authors from 3379 institutions in 83 countries/regions contributed to 2916 documents that were published in 712 academic journals. Annual publication output followed exponential growth since 2008. The United States, the University of Pittsburgh, and the American Journal of Physiology-Renal Physiology were the most productive countries, institutions, and journals in terms of research outputs, respectively. The area of interest has shifted from neutrophil gelatinase-associated lipocalin, cell cycle, and tubular damage toward sepsis and COVID-19. Apoptosis, inflammation, and chronic kidney disease have become popular in recent years, and studies on ferroptosis, machine learning, COVID-19, and renal fibrosis will be the focus of future research.
This bibliometric study suggests that future research on AKI biomarkers would focus on ferroptosis, renal fibrosis and COVID-19. Artificial intelligence, such as machine learning, maybe the most promising direction for the discovery and validation of AKI biomarkers.
急性肾损伤(AKI)是一种常见的全球性疾病,具有较高的发病率和死亡率。生物标志物可辅助 AKI 的诊断、预测、干预和预后评估。本研究旨在通过文献计量学分析总结 AKI 生物标志物的研究现状,并确定研究热点。
从 Web of Science 核心合集的科学引文索引扩展版中检索相关的原始英文文献,检索时间截至 2022 年 12 月 31 日。收集并分析所有文献的全文记录和相关引用参考文献。
来自 83 个国家/地区的 3379 个机构的 16368 位作者共发表了 2916 篇发表在 712 种学术期刊上的文献。自 2008 年以来,年发表量呈指数级增长。美国、匹兹堡大学和美国生理学杂志-肾脏生理学在研究成果方面是最具生产力的国家、机构和期刊。研究兴趣已从中性粒细胞明胶酶相关脂质运载蛋白、细胞周期和肾小管损伤转移到脓毒症和 COVID-19。近年来,细胞凋亡、炎症和慢性肾脏病成为研究热点,铁死亡、机器学习、COVID-19 和肾脏纤维化的研究将成为未来研究的重点。
本计量学研究表明,未来 AKI 生物标志物的研究将集中在铁死亡、肾脏纤维化和 COVID-19 上。人工智能,如机器学习,可能是 AKI 生物标志物发现和验证最有前途的方向。